Patents Assigned to Shuttle Pharmaceuticals, Inc.
  • Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation
    Patent number: 12357650
    Abstract: Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.
    Type: Grant
    Filed: December 4, 2023
    Date of Patent: July 15, 2025
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Olga Timofeeva, Milton Brown, Anatoly Dritschilo
  • Selective histone deacetylase inhibitors for the treatment of human disease
    Patent number: 12077515
    Abstract: Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: September 3, 2024
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Anatoly Dritschilo
  • Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
    Patent number: 11654157
    Abstract: Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: May 23, 2023
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Olga Timofeeva, Milton Brown, Anatoly Dritschilo
  • Selective histone deacetylase inhibitors for the treatment of human disease
    Patent number: 11584733
    Abstract: Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: February 21, 2023
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • Selective histone deacetylase inhibitors for the treatment of human disease
    Patent number: 11407723
    Abstract: Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: August 9, 2022
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Anatoly Dritschilo
  • Selective histone deacetylase inhibitors for the treatment of human disease
    Patent number: 11034667
    Abstract: Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 15, 2021
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
    Patent number: 10745352
    Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: August 18, 2020
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
    Patent number: 10730834
    Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: August 4, 2020
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo